{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:09:47Z","timestamp":1791407387013,"version":"4.3.3"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:00:00Z","timestamp":1492473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s10741-017-9612-9","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T01:35:24Z","timestamp":1492479324000},"page":"289-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Drug-induced pulmonary arterial hypertension: a review"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9387-4369","authenticated-orcid":false,"given":"Lohit","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyoo","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Khaddour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishin","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahek","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavinkumar D.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,18]]},"reference":[{"issue":"Suppl","key":"9612_CR1","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","volume":"62","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(Suppl):D42\u2013D50","journal-title":"J Am Coll Cardiol"},{"key":"9612_CR2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJM199701093360207","volume":"336","author":"LJ Rubin","year":"1997","unstructured":"Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111\u2013117","journal-title":"N Engl J Med"},{"key":"9612_CR3","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Noordegraaf AV, Beghetti M, Ghofrani A (2015) ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J ehv317"},{"issue":"Suppl. 1","key":"9612_CR4","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","volume":"54","author":"G Simonneau","year":"2009","unstructured":"Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(Suppl. 1):S43\u2013S54","journal-title":"J Am Coll Cardiol"},{"key":"9612_CR5","first-page":"818","volume":"115","author":"HP Gurtner","year":"1985","unstructured":"Gurtner HP (1985) Chronic pulmonary hypertension of vascular aetiology, plexogenic pulmonary arteriopathy and the appetite depressant Aminorex: lessons from an epidemic. Schweiz Med Wochenschr 115:818\u2013827","journal-title":"Schweiz Med Wochenschr"},{"key":"9612_CR6","first-page":"160","volume":"27","author":"HP Gurtner","year":"1985","unstructured":"Gurtner HP (1985) Aminorex and pulmonary hypertension: a review. Cor Vasa 27:160\u2013171","journal-title":"Cor Vasa"},{"key":"9612_CR7","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1172\/JCI33452","volume":"118","author":"M Rabinovitch","year":"2008","unstructured":"Rabinovitch M (2008) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118:2372\u20132237","journal-title":"J Clin Invest"},{"issue":"1","key":"9612_CR8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/01.CIR.99.1.156","volume":"99","author":"AP Fishman","year":"1999","unstructured":"Fishman AP (1999) Aminorex to fen\/phen: an epidemic foretold. Circulation 99(1):156\u2013161","journal-title":"Circulation"},{"key":"9612_CR9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/rr181","volume":"3","author":"S Eddahibi","year":"2002","unstructured":"Eddahibi S, Adnot S (2002) Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir Res 3:9","journal-title":"Respir Res"},{"issue":"3 Suppl","key":"9612_CR10","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.1378\/chest.121.3_suppl.97S","volume":"121","author":"S Eddahibi","year":"2002","unstructured":"Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S (2002) Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest 121(3 Suppl):97S\u201398S","journal-title":"Chest"},{"issue":"4","key":"9612_CR11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1067\/mlc.2002.122181","volume":"139","author":"S Eddahibi","year":"2002","unstructured":"Eddahibi S, Raffestin B, Hamon M, Adnot S (2002) Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med 139(4):194\u2013201","journal-title":"J Lab Clin Med"},{"issue":"5","key":"9612_CR12","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1378\/chest.118.5.1496","volume":"118","author":"SP Gaine","year":"2000","unstructured":"Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, Traill TA (2000) Recreational use of aminorex and pulmonary hypertension. Chest 118(5):1496\u20131497","journal-title":"Chest"},{"issue":"3","key":"9612_CR13","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1172\/JCI111499","volume":"74","author":"MD McGoon","year":"1984","unstructured":"McGoon MD, Vanhoutte PM (1984) Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 74(3):828\u2013833","journal-title":"J Clin Invest"},{"issue":"3","key":"9612_CR14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1073\/pnas.83.3.674","volume":"83","author":"GM Nemecek","year":"1986","unstructured":"Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA (1986) Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A 83(3):674\u2013678","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"9612_CR15","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nm764","volume":"8","author":"JM Launay","year":"2002","unstructured":"Launay JM, Herv\u00e9 P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8(10):1129\u20131135","journal-title":"Nat Med"},{"issue":"10","key":"9612_CR16","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1161\/CIRCULATIONAHA.105.556704","volume":"112","author":"Z Hong","year":"2005","unstructured":"Hong Z, Smith AJ, Archer SL, Wu XC, Nelson DP, Peterson D, Johnson G, Weir EK (2005) Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation 112(10):1494\u20131499","journal-title":"Circulation"},{"issue":"8","key":"9612_CR17","first-page":"1169","volume":"76","author":"BT Winslow","year":"2007","unstructured":"Winslow BT, Voorhees KI, Pehl KA (2007) Methamphetamine abuse. Am Fam Physician 76(8):1169\u20131174","journal-title":"Am Fam Physician"},{"issue":"23","key":"9612_CR18","first-page":"1283","volume":"149","author":"SA Wolferen van","year":"2005","unstructured":"van Wolferen SA, Vonk Noordegraaf A, Boonstra A, Postmus PE (2005) Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping. Ned Tijdschr Geneeskd 149(23):1283\u20131288","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"3","key":"9612_CR19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0954-6111(96)90160-2","volume":"90","author":"J Collazos","year":"1996","unstructured":"Collazos J, Mart\u00ednez E, Fern\u00e1ndez A, Mayo J (1996) Acute, reversible pulmonary hypertension associated with cocaine use. Respir Med 90(3):171\u2013174","journal-title":"Respir Med"},{"issue":"2","key":"9612_CR20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0002-8703(95)90459-X","volume":"130","author":"DL Yakel Jr","year":"1995","unstructured":"Yakel DL Jr, Eisenberg MJ (1995) Pulmonary artery hypertension in chronic intravenous cocaine users. Am Heart J 130(2):398\u2013399","journal-title":"Am Heart J"},{"issue":"2","key":"9612_CR21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1378\/chest.104.2.614","volume":"104","author":"PH Schaiberger","year":"1993","unstructured":"Schaiberger PH, Kennedy TC, Miller FC, Gal J, Petty TL (1993) Pulmonary hypertension associated with long-term inhalation of \u201ccrank\u201d methamphetamine. Chest 104(2):614\u2013616","journal-title":"Chest"},{"issue":"6","key":"9612_CR22","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1378\/chest.130.6.1657","volume":"130","author":"KM Chin","year":"2006","unstructured":"Chin KM, Channick RN, Rubin LJ (2006) Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 130(6):1657\u20131663","journal-title":"Chest"},{"issue":"4","key":"9612_CR23","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1378\/chest.07-0235","volume":"132","author":"RB Rothman","year":"2007","unstructured":"Rothman RB, Baumann MH (2007) Methamphetamine and idiopathic pulmonary arterial hypertension: role of the serotonin transporter. Chest 132(4):1412\u20131413","journal-title":"Chest"},{"key":"9612_CR24","unstructured":"Center for Behavioral Health Statistics and Quality (2015) Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health"},{"issue":"2","key":"9612_CR25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1378\/chest.11-0426","volume":"141","author":"IA Dhalla","year":"2012","unstructured":"Dhalla IA, Juurlink DN, Gomes T, Granton JT, Zheng H, Mamdani MM (2012) Selective serotonin reuptake inhibitors and pulmonary arterial hypertension: a case\u2013control study. Chest 141(2):348\u2013353","journal-title":"Chest"},{"issue":"6","key":"9612_CR26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJMoa052744","volume":"354","author":"CD Chambers","year":"2006","unstructured":"Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354(6):579\u2013587","journal-title":"N Engl J Med"},{"issue":"21","key":"9612_CR27","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2015.5605","volume":"313","author":"KF Huybrechts","year":"2015","unstructured":"Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C, Levin R, Mogun H, Hernandez-Diaz S (2015) Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 313(21):2142\u20132151","journal-title":"JAMA"},{"key":"9612_CR28","first-page":"23","volume":"10","author":"J Emole","year":"2016","unstructured":"Emole J, Talabi T, Pinilla-Ibarz J (2016) Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib. Biologics 10:23\u201331","journal-title":"Biologics"},{"issue":"24","key":"9612_CR29","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","volume":"125","author":"Y Chalandon","year":"2015","unstructured":"Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lh\u00e9ritier V, Chevret S, Ifrah N, Dombret H, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) (2015) Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 125(24):3711\u20133719","journal-title":"Blood"},{"issue":"1","key":"9612_CR30","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.leukres.2011.08.007","volume":"36","author":"EM Orlandi","year":"2012","unstructured":"Orlandi EM, Rocca B, Pazzano AS, Ghio S (2012) Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 36(1):e4\u2013e6","journal-title":"Leuk Res"},{"key":"9612_CR31","doi-asserted-by":"crossref","unstructured":"Yun S, Anwer F, Vincelette ND (2014) Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia. BMJ Case Rep","DOI":"10.1136\/bcr-2014-204477"},{"issue":"1","key":"9612_CR32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5543\/tkda.2015.41763","volume":"43","author":"G Ta\u00e7oy","year":"2015","unstructured":"Ta\u00e7oy G, \u00c7engel A, \u00d6zkurt ZN, T\u00fcrko\u011flu S (2015) Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. Turk Kardiyol Dern Ars 43(1):78\u201381","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"11","key":"9612_CR33","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","volume":"90","author":"NP Shah","year":"2015","unstructured":"Shah NP, Wallis N, Farber HW et al (2015) Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 90(11):1060\u20131064","journal-title":"Am J Hematol"},{"issue":"17","key":"9612_CR34","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani D, Bergot E, Gunther S et al (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125(17):2128\u20132137","journal-title":"Circulation"},{"issue":"5","key":"9612_CR35","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1055\/s-0033-1356494","volume":"34","author":"L Godinas","year":"2013","unstructured":"Godinas L, Guignabert C, Seferian A et al (2013) Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Semin Respir Crit Care Med 34(5):714\u2013724","journal-title":"Semin Respir Crit Care Med"},{"issue":"5","key":"9612_CR36","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1378\/chest.97.5.1032","volume":"97","author":"HD Tazelaar","year":"1990","unstructured":"Tazelaar HD, Myers JL, Drage CW, King TE Jr, Aguayo S, Colby TV (1990) Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features. Chest 97(5):1032\u20131036","journal-title":"Chest"},{"issue":"2","key":"9612_CR37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0002-9343(91)80175-L","volume":"90","author":"M Yakovlevitch","year":"1991","unstructured":"Yakovlevitch M, Siegel M, Hoch DH, Rutlen DL (1991) Pulmonary hypertension in a patient with tryptophan-induced eosinophilia-myalgia syndrome. Am J Med 90(2):272\u2013273","journal-title":"Am J Med"},{"issue":"6","key":"9612_CR38","first-page":"867","volume":"18","author":"PA Hertzman","year":"1991","unstructured":"Hertzman PA, Falk H, Kilbourne EM, Page S, Shulman LE (1991) The eosinophilia-myalgia syndrome: the Los Alamos Conference. J Rheumatol 18(6):867\u2013873","journal-title":"J Rheumatol"},{"issue":"11","key":"9612_CR39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00011-005-1380-7","volume":"54","author":"MJ Smith","year":"2005","unstructured":"Smith MJ, Garrett RH (2005) A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation. Inflamm Res 54(11):435\u2013450 Review","journal-title":"Inflamm Res"},{"key":"9612_CR40","unstructured":"DeVita VT (2011) Alkylating agnets. In: Alkylating agents were the first anticancer molecules developed, and they are still used today, 9th edn. Wolters Kluwer Health\/Lippincott Williams & Wilkins, p 189\u2013195"},{"issue":"2","key":"9612_CR41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ajpath.2014.10.021","volume":"185","author":"B Ranchoux","year":"2015","unstructured":"Ranchoux B, Gunther S, Quarck R et al (2015) Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 185(2):356\u2013371","journal-title":"Am J Pathol"},{"issue":"5","key":"9612_CR42","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/01.CIR.80.5.1198","volume":"80","author":"GG Pietra","year":"1989","unstructured":"Pietra GG, Edwards WD, Kay JM et al (1989) Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the national heart, lung, and blood institute, primary pulmonary hypertension registry. Circulation 80(5):1198\u20131206","journal-title":"Circulation"},{"issue":"5","key":"9612_CR43","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1378\/chest.109.5.1388","volume":"109","author":"LM Williams","year":"1996","unstructured":"Williams LM, Fussell S, Veith RW, Nelson S, Mason CM (1996) Pulmonary veno-occlusive disease in an adult following bone marrow transplantation: case report and review of the literature. Chest 109(5):1388\u20131391","journal-title":"Chest"},{"issue":"1","key":"9612_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2141.2003.04423.x","volume":"123","author":"M Mukai","year":"2003","unstructured":"Mukai M, Kondo M, Bohgaki T, Notoya A, Kohno M (2003) Pulmonary veno-occlusive disease following allogeneic peripheral blood stem cell transplantation for chronic myeloid leukaemia. Br J Haematol 123(1):1","journal-title":"Br J Haematol"},{"issue":"5","key":"9612_CR45","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1378\/chest.92.5.871","volume":"92","author":"CM Lombard","year":"1987","unstructured":"Lombard CM, Churg A, Winokur S (1987) Pulmonary veno-occlusive disease following therapy for malignant neoplasms. Chest 92(5):871\u2013876","journal-title":"Chest"},{"issue":"2","key":"9612_CR46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0169-5002(01)00479-2","volume":"36","author":"F Gagnadoux","year":"2002","unstructured":"Gagnadoux F, Capron F, Lebeau B (2002) Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma. Lung Cancer 36(2):213\u2013215","journal-title":"Lung Cancer"},{"issue":"12","key":"9612_CR47","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1089\/jir.2011.0101","volume":"31","author":"D Choubey","year":"2011","unstructured":"Choubey D, Moudgil KD (2011) Interferons in autoimmune and inflammatory diseases: regulation and roles. J Interf Cytokine Res 31(12):857\u2013865","journal-title":"J Interf Cytokine Res"},{"issue":"2","key":"9612_CR48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri3133","volume":"12","author":"JM Gonzalez-Navajas","year":"2012","unstructured":"Gonzalez-Navajas JM, Lee J, David M, Raz E (2012) Immunomodulatory functions of type I interferons. Nat Rev Immunol 12(2):125\u2013135","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"9612_CR49","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.1995.13.9.2401","volume":"13","author":"S Sacchi","year":"1995","unstructured":"Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M (1995) Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 13(9):2401\u20132407","journal-title":"J Clin Oncol"},{"issue":"6","key":"9612_CR50","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s10620-010-1220-7","volume":"55","author":"S Dhillon","year":"2010","unstructured":"Dhillon S, Kaker A, Dosanjh A, Japra D, Vanthiel DH (2010) Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci 55(6):1785\u20131790","journal-title":"Dig Dis Sci"},{"key":"9612_CR51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-7120-3-26","volume":"3","author":"N Jochmann","year":"2005","unstructured":"Jochmann N, Kiecker F, Borges AC et al (2005) Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. Cardiovasc Ultrasound 3:26","journal-title":"Cardiovasc Ultrasound"},{"issue":"1","key":"9612_CR52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajh.10319","volume":"73","author":"P Anderson","year":"2003","unstructured":"Anderson P, Hoglund M, Rodjer S (2003) Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies. Am J Hematol 73(1):54\u201358","journal-title":"Am J Hematol"},{"issue":"2","key":"9612_CR53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-2999(99)00107-7","volume":"370","author":"M Hanaoka","year":"1999","unstructured":"Hanaoka M, Kubo K, Hayano T, Koizumi T, Kobayashi T (1999) Interferon-alpha elevates pulmonary blood pressure in sheep\u2014the role of thromboxane cascade. Eur J Pharmacol 370(2):145\u2013151","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"9612_CR54","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/1352458509104593","volume":"15","author":"AH Ledinek","year":"2009","unstructured":"Ledinek AH, Jazbec SS, Drinovec I, Rot U (2009) Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report. Mult Scler 15(7):885\u2013886","journal-title":"Mult Scler"},{"issue":"4","key":"9612_CR55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000335064","volume":"120","author":"S Caravita","year":"2011","unstructured":"Caravita S, Secchi MB, Wu SC, Pierini S, Paggi A (2011) Sildenafil therapy for interferon-beta-1a-induced pulmonary arterial hypertension: a case report. Cardiology 120(4):187\u2013189","journal-title":"Cardiology"},{"key":"9612_CR56","doi-asserted-by":"crossref","unstructured":"Pol S, Sulkowski MS, Hassanein T et al (2015) Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed. Hepatology 62:129\u2013134.","DOI":"10.1002\/hep.27836"},{"key":"9612_CR57","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/eb-2013-101592","volume":"19","author":"MC Ferguson","year":"2014","unstructured":"Ferguson MC (2014) Sofosbuvir with ribavirin is safe and effective in hepatitis C genotype 1 with unfavourable pretreatment characteristics. Evid Based Med 19:90","journal-title":"Evid Based Med"},{"key":"9612_CR58","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27922","volume":"62","author":"V Saxena","year":"2015","unstructured":"Saxena V, Nyberg L, Pauly M et al (2015) Safety and efficacy of simeprevir\/sofosbuvir in hepatitis C\u2013infected patients with compensated and decompensated cirrhosis. Hepatology 62:715\u2013725","journal-title":"Hepatology"},{"issue":"Suppl 5","key":"9612_CR59","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.dld.2014.09.026","volume":"46","author":"A Mangia","year":"2014","unstructured":"Mangia A, Piazzolla V (2014) Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies. Dig Liver Dis 46(Suppl 5):S179\u2013S185","journal-title":"Dig Liver Dis"},{"issue":"3","key":"9612_CR60","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/j.chest.2015.09.018","volume":"149","author":"S Renard","year":"2016","unstructured":"Renard S, Borentain P, Salaun E, Benhaourech S, Maille B, Darque A, Bregigeon S, Colson P, Laugier D, Gaubert MR, Habib G (2016) Severe pulmonary arterial hypertension in patients treated for hepatitis C with sofosbuvir. Chest 149(3):e69\u2013e73. doi: 10.1016\/j.chest.2015.09.018","journal-title":"Chest"},{"issue":"6","key":"9612_CR61","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1183\/09031936.00057914","volume":"44","author":"L Savale","year":"2014","unstructured":"Savale L, Sattler C, Gunther S et al (2014) Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 44(6):1627\u20131634","journal-title":"Eur Respir J"},{"key":"9612_CR62","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2165\/00003495-200262110-00003","volume":"62","author":"MT Nurmohamed","year":"2002","unstructured":"Nurmohamed MT, van Halm VP, Dijkmans BA (2002) Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 62:1599\u20131609","journal-title":"Drugs"},{"key":"9612_CR63","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/rheumatology\/keh328","volume":"43","author":"VM Martinez-Taboada","year":"2004","unstructured":"Martinez-Taboada VM, Rodriguez-Valverde V, Gonzalez-Vilchez F, Armijo JA (2004) Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide. Rheumatology (Oxford) 43:1451\u20131453","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"9612_CR64","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12012-012-9153-3","volume":"12","author":"PA Alvarez","year":"2012","unstructured":"Alvarez PA, Saad AK, Flagel S, Mazzocchi O, Blanco MV (2012) Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report. Cardiovasc Toxicol 12(2):180\u2013183","journal-title":"Cardiovasc Toxicol"},{"key":"9612_CR65","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keg038","volume":"42","author":"D Burger","year":"2003","unstructured":"Burger D, Begue-Pastor N, Benavent S, Gruaz L, Kaufmann MT, Chicheportiche R et al (2003) The active metabolite of leflunomide, a77 1726, inhibits the production of prostaglandin e(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 42:89\u201396","journal-title":"Rheumatology (Oxford)"},{"key":"9612_CR66","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-3565(24)36813-2","volume":"282","author":"AP Curnock","year":"1997","unstructured":"Curnock AP, Robson PA, Yea CM, Moss D, Gadher S, Thomson TA et al (1997) Potencies of leflunomide and hr325 as inhibitors of prostaglandin endoperoxide h synthase-1 and \u22122: comparison with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 282:339\u2013347","journal-title":"J Pharmacol Exp Ther"},{"key":"9612_CR67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0161-4630(80)90078-6","volume":"4","author":"UN Das","year":"1980","unstructured":"Das UN (1980) Possible role of prostaglandins in the pathogenesis of pulmonary hypertension. Prostaglandins Med 4:163\u2013170","journal-title":"Prostaglandins Med"},{"key":"9612_CR68","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3382\/ps.2007-00334","volume":"87","author":"S Stebel","year":"2008","unstructured":"Stebel S, Wideman RF (2008) Pulmonary hemodynamic responses to intravenous prostaglandin e2 in broiler chickens. Poult Sci 87:138\u2013145","journal-title":"Poult Sci"},{"key":"9612_CR69","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1161\/CIRCULATIONAHA.107.716241","volume":"117","author":"LE Fredenburgh","year":"2008","unstructured":"Fredenburgh LE, Liang OD, Macias AA, Polte TR, Liu X, Riascos DF et al (2008) Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation 117:2114\u20132122","journal-title":"Circulation"},{"issue":"9","key":"9612_CR70","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, JF DP, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807","journal-title":"N Engl J Med"},{"issue":"3","key":"9612_CR71","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.leu.2404943","volume":"22","author":"A Cortelezzi","year":"2008","unstructured":"Cortelezzi A, Gritti G, Del Papa N, Pasquini MC, Calori R, Gianelli U, Cortiana M, Parati G, Onida F, Sozzi F, Vener C, Bianchi P, Deliliers GL (2008) Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia 22(3):646\u2013649","journal-title":"Leukemia"},{"issue":"6","key":"9612_CR72","first-page":"e244-5","volume":"100","author":"AT Low","year":"2015","unstructured":"Low AT, Howard L, Harrison C, Tulloh RM (2015) Pulmonary arterial hypertension exacerbated by ruxolitinib. Haematologica 100(6):e244-5","journal-title":"Haematologica"},{"issue":"4","key":"9612_CR73","first-page":"223","volume":"1","author":"R Paulin","year":"2012","unstructured":"Paulin R, Meloche J, Bonnet S (2012) STAT3 signaling in pulmonary arterial hypertension. JAKSTAT 1(4):223\u2013233","journal-title":"JAKSTAT"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-017-9612-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-017-9612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-017-9612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T22:41:06Z","timestamp":1750200066000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-017-9612-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,18]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["9612"],"URL":"https:\/\/doi.org\/10.1007\/s10741-017-9612-9","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,18]]}}}